FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1982135989> ?p ?o ?g. }

• W1982135989 endingPage "2511" @default.
• W1982135989 startingPage "2504" @default.
• W1982135989 abstract "BACKGROUND. Acute myeloid leukemia (AML) carries a dismal prognosis in older patients. In this study, the authors evaluated the safety and efficacy of arsenic trioxide combined with low-dose cytarabine in untreated patients aged ≥60 years with AML. METHODS. In a phase 1/2 design, arsenic trioxide was administered intravenously at a dose of 0.25 mg/kg on Days 1 through 5 and on Days 8 through 12, and low-dose cytarabine was given subcutaneously twice daily on Days 1 through 14 in escalating doses to a target of 10 mg/m2 per dose. Of 64 patients who had pathologically confirmed AML, excluding patients with acute promyelocytic leukemia and using World Health Organization criteria, the median age was 71 years, 10 patients (16%) had treatment-related AML, 40 patients (63%) had an antecedent myelodysplastic syndrome or myeloproliferative disorder, and 35 patients (55%) had unfavorable cytogenetics. Thirty-four patients (53%) had an Eastern Cooperative Oncology Group performance status of 2 or 3. RESULTS. Complete remission was achieved in 21 of 61 patients (34%), including 15 of 50 patients (30%) who had secondary or treatment-related AML, 10 of 33 patients (30%) who had unfavorable cytogenetics, and 6 of 34 patients (18%) who had a poor baseline performance status. The mortality rate within the first 4 weeks was 8%. Neutropenic fever was observed in >80% of patients, and 41% of patients had bacteremia. Nonhematologic toxicity generally was mild and reversible and included fatigue, nausea, diarrhea, rash, peripheral edema, and elevated transaminases. There were no clinically significant cardiac arrhythmias. CONCLUSIONS. The addition of arsenic trioxide to low-dose cytarabine appeared to improve responses in elderly patients who had AML compared with either agent alone, and a randomized trial of the combination versus single-agent low-dose cytarabine is ongoing. Cancer 2008. © 2008 American Cancer society." @default.
• W1982135989 created "2016-06-24" @default.
• W1982135989 creator A5004303439 @default.
• W1982135989 creator A5012863731 @default.
• W1982135989 creator A5024592292 @default.
• W1982135989 creator A5035164689 @default.
• W1982135989 creator A5040539933 @default.
• W1982135989 creator A5050393309 @default.
• W1982135989 creator A5054861922 @default.
• W1982135989 creator A5056731172 @default.
• W1982135989 creator A5061056521 @default.
• W1982135989 creator A5065354635 @default.
• W1982135989 creator A5068345170 @default.
• W1982135989 creator A5078887304 @default.
• W1982135989 date "2008-11-01" @default.
• W1982135989 modified "2023-10-16" @default.
• W1982135989 title "Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia" @default.
• W1982135989 cites W1832802185 @default.
• W1982135989 cites W1963335440 @default.
• W1982135989 cites W1970946990 @default.
• W1982135989 cites W1981540618 @default.
• W1982135989 cites W1985165035 @default.
• W1982135989 cites W2026035187 @default.
• W1982135989 cites W2029409133 @default.
• W1982135989 cites W2039699322 @default.
• W1982135989 cites W2043578136 @default.
• W1982135989 cites W2064116421 @default.
• W1982135989 cites W2068556430 @default.
• W1982135989 cites W2070012795 @default.
• W1982135989 cites W2081576971 @default.
• W1982135989 cites W2109065151 @default.
• W1982135989 cites W2109685720 @default.
• W1982135989 cites W2124013844 @default.
• W1982135989 cites W2133918059 @default.
• W1982135989 cites W2159256284 @default.
• W1982135989 cites W2204518675 @default.
• W1982135989 cites W2318674152 @default.
• W1982135989 cites W2339692928 @default.
• W1982135989 cites W27031567 @default.
• W1982135989 cites W66419860 @default.
• W1982135989 doi "https://doi.org/10.1002/cncr.23855" @default.
• W1982135989 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18825661" @default.
• W1982135989 hasPublicationYear "2008" @default.
• W1982135989 type Work @default.
• W1982135989 sameAs 1982135989 @default.
• W1982135989 citedByCount "45" @default.
• W1982135989 countsByYear W19821359892012 @default.
• W1982135989 countsByYear W19821359892013 @default.
• W1982135989 countsByYear W19821359892014 @default.
• W1982135989 countsByYear W19821359892015 @default.
• W1982135989 countsByYear W19821359892017 @default.
• W1982135989 countsByYear W19821359892018 @default.
• W1982135989 countsByYear W19821359892019 @default.
• W1982135989 countsByYear W19821359892020 @default.
• W1982135989 countsByYear W19821359892021 @default.
• W1982135989 countsByYear W19821359892022 @default.
• W1982135989 crossrefType "journal-article" @default.
• W1982135989 hasAuthorship W1982135989A5004303439 @default.
• W1982135989 hasAuthorship W1982135989A5012863731 @default.
• W1982135989 hasAuthorship W1982135989A5024592292 @default.
• W1982135989 hasAuthorship W1982135989A5035164689 @default.
• W1982135989 hasAuthorship W1982135989A5040539933 @default.
• W1982135989 hasAuthorship W1982135989A5050393309 @default.
• W1982135989 hasAuthorship W1982135989A5054861922 @default.
• W1982135989 hasAuthorship W1982135989A5056731172 @default.
• W1982135989 hasAuthorship W1982135989A5061056521 @default.
• W1982135989 hasAuthorship W1982135989A5065354635 @default.
• W1982135989 hasAuthorship W1982135989A5068345170 @default.
• W1982135989 hasAuthorship W1982135989A5078887304 @default.
• W1982135989 hasBestOaLocation W19821359891 @default.
• W1982135989 hasConcept C104317684 @default.
• W1982135989 hasConcept C126322002 @default.
• W1982135989 hasConcept C141071460 @default.
• W1982135989 hasConcept C185592680 @default.
• W1982135989 hasConcept C190283241 @default.
• W1982135989 hasConcept C2776601000 @default.
• W1982135989 hasConcept C2778041864 @default.
• W1982135989 hasConcept C2778461978 @default.
• W1982135989 hasConcept C2778570526 @default.
• W1982135989 hasConcept C2778729363 @default.
• W1982135989 hasConcept C2780386689 @default.
• W1982135989 hasConcept C2780580376 @default.
• W1982135989 hasConcept C2781121885 @default.
• W1982135989 hasConcept C55493867 @default.
• W1982135989 hasConcept C71924100 @default.
• W1982135989 hasConcept C90924648 @default.
• W1982135989 hasConceptScore W1982135989C104317684 @default.
• W1982135989 hasConceptScore W1982135989C126322002 @default.
• W1982135989 hasConceptScore W1982135989C141071460 @default.
• W1982135989 hasConceptScore W1982135989C185592680 @default.
• W1982135989 hasConceptScore W1982135989C190283241 @default.
• W1982135989 hasConceptScore W1982135989C2776601000 @default.
• W1982135989 hasConceptScore W1982135989C2778041864 @default.
• W1982135989 hasConceptScore W1982135989C2778461978 @default.
• W1982135989 hasConceptScore W1982135989C2778570526 @default.
• W1982135989 hasConceptScore W1982135989C2778729363 @default.
• W1982135989 hasConceptScore W1982135989C2780386689 @default.
• W1982135989 hasConceptScore W1982135989C2780580376 @default.

• next